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Background. In 2015, the laboratory at the Ebola treatment center in Coyah, Guinea, confirmed Ebola virus disease (EVD) in 
286 patients. The cycle threshold (Ct) of an Ebola virus–specific reverse transcription–polymerase chain reaction assay and 13 blood 
chemistry parameters were measured on admission and during hospitalization. Favipiravir treatment was offered to patients with 
EVD on a compassionate-use basis.
Methods. To reduce biases in the raw field data, we carefully selected 163 of 286 patients with EVD for a retrospective study to 
assess associations between potential risk factors, alterations in blood chemistry findings, favipiravir treatment, and outcome.
Results. The case-fatality rate in favipiravir-treated patients was lower than in untreated patients (42.5% [31 of 73] vs 57.8% 
[52 of 90]; P = .053 by univariate analysis). In multivariate regression analysis, a higher Ct and a younger age were associated with 
survival (P < .001), while favipiravir treatment showed no statistically significant effect (P = .11). However, Kaplan-Meier analysis 
indicated a longer survival time in the favipiravir-treated group (P = .015). The study also showed characteristic changes in blood 
chemistry findings in patients who died, compared with survivors.
Conclusions. Consistent with the JIKI trial, this retrospective study revealed a trend toward improved survival in favipiravir- 
treated patients; however, the effect of treatment was not statistically significant, except for its influence on survival time.
Keywords. Filovirus; Ebola virus disease; Favipiravir; Guinea; epidemic; mobile laboratory.
The 2013–2016 West African Ebola virus disease (EVD) out-
break originated in Guinea and rapidly spread to neighboring 
countries. Unprecedented in its duration and scale, the out-
break resulted in > 28 000 suspected, probable, and confirmed 
cases and >11 000 deaths in Guinea, Liberia, and Sierra Leone 
[1]. A fatal outcome of EVD is associated with age, a high viral 
load, severe acute kidney injury, and elevated liver enzyme lev-
els [2–15]. Various investigational therapeutic agents, including 
the broad-spectrum antiviral drug favipiravir, monoclonal an-
tibody cocktails, small interfering RNA, and interferon, have 
been evaluated in patients during the 2013–2016 EVD outbreak 
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[16–19]. After completion of the JIKI clinical trial for favi-
piravir in Guinea [18], the drug was offered to patients on a 
compassionate-use basis.
In March 2014, a laboratory unit of the European Mobile 
Laboratory (EMLab) consortium was deployed to the EVD 
treatment center (ETC) in Guéckédou, Guinea, to provide lab-
oratory diagnostic service [15]. In response to the increasing 
number of EVD cases in western Guinea, the unit was relocated 
to the ETC in Coyah, where it was operational from February to 
December 2015. During this period, EMLab tested 7000 sam-
ples by an Ebola virus (EBOV)–specific reverse transcription–
polymerase chain reaction (RT-PCR) assay. Here, we report 
the analysis of the laboratory data generated in Coyah and the 
results of a retrospective study aiming to assess associations 
between potential risk factors, compassionate use of favipiravir, 
and EVD outcome.
METHODS
Patients and Treatment
Blood specimens were collected from individuals with sus-
pected EVD attending an ETC and tested for EBOV by 
RT-PCR. Most suspected cases originated from the regions 
of Kindia (3945 [85%]), Boké (454 [9.8%]), and Conakry (43 
[0.93%]). Laboratory-confirmed cases were admitted to an 
ETC and received supportive treatment, including (1) oral 
rehydration therapy and/or intravenous fluids; (2) correc-
tion of electrolyte abnormalities, based on blood chemistry 
findings; (3) symptomatic care with antipyretics, anti-emet-
ics, and antidiarrheal agents; (4) preemptive treatment of 
concomitant infections, using drugs such as broad-spectrum 
antibiotics and antimalarials; (5) nutritional support; and (6) 
psychological care. Patients were also offered specific treat-
ment with oral favipiravir on a compassionate-use basis. 
The favipiravir treatment team aimed to offer the drug to all 
patients with laboratory-confirmed EVD, and except for the 
eligibility criteria (>1 year of age, no pregnancy, and ability 
to take oral drug), no further selection criteria were applied. 
Reasons given by patients for not consenting to participa-
tion were not recorded, although concurrently conducted 
clinical trials (see below) interfered with recruitment. The 
dosing scheme was identical to that of the prior JIKI trial, 
with a loading dose of 6000 mg on the first day followed by 
2400 mg/days for 9 days [18]. All favipiravir-treated patients 
completed the 10-day treatment course or died while receiv-
ing treatment. Interferon β1a (IFN-β1a) or a combination 
of favipiravir with ZMapp was given to a small number of 
patients in the framework of clinical trials, as reported previ-
ously [17, 19]. The majority of patients with EVD confirmed 
by the EMLab in Coyah were admitted to the ETC in Coyah. 
Throat swab specimens from individuals who died in the 
community were tested by EBOV RT-PCR.
Diagnostic Assays
All laboratory data were generated by the EMLab unit at the 
ETC in Coyah. Viral RNA was extracted with the QIAamp 
Viral RNA Mini Kit (Qiagen) from whole blood specimens 
mixed with EDTA, other body-fluid specimens, or swab spec-
imens. EBOV RNA was detected using the RealStar Filovirus 
Screen RT-PCR kit, version 1.0 (until March 2015; Altona 
Diagnostics), or the RealStar Zaire Ebolavirus RT-PCR kit, 
version 1.0 (from March 2015 onward; Altona Diagnostics), 
using the SmartCycler II system (Cepheid; until June 2015) or 
the Rotor-Gene Q system (Qiagen; from March 2015 onward). 
Although these assays slightly differ in terms of sensitivity, they 
produce virtually identical cycle thresholds (Cts) [20]. Cts were 
reported to clinicians as a semiquantitative measure of viral 
load. Plasmodium falciparum, Plasmodium vivax, Plasmodium 
malariae, and Plasmodium ovale antigens in blood specimens 
were detected using the BinaxNow Malaria (Alere) rapid diag-
nostic test (RDT).
Blood Chemistry Analysis
Blood levels of alanine aminotransferase (ALT), albumin, amy-
lase, aspartate aminotransferase (AST), calcium, C-reactive 
protein (CRP), creatine kinase (CK), creatinine, glucose, potas-
sium, sodium, total bilirubin, and blood urea nitrogen (BUN) 
were analyzed in the EMLab unit, using a Piccolo Xpress 
Chemistry Analyzer with Amlyte 13 Reagent Discs (Abaxis) 
according to the manufacturer’s instructions.
Data Management
Demographic patient data was provided on the laboratory 
request forms accompanying the samples by hospital staff, 
contact-tracing teams, and other partners in the field. Patient 
name, age, sex, residence, ETC patient identifier, sample identi-
fier, sample type, collection date, date of symptom onset, EBOV 
RT-PCR result (with the corresponding Ct), and malaria RDT 
result were captured in the EMLab database (Excel, Microsoft) 
and reported to national authorities and the World Health 
Organization (WHO) on a daily basis.
To facilitate the assignment of multiple samples to individual 
patients, validate the demographic information, and document 
the outcome, the EMLab database was manually merged with 
the Guinean database of patients with EVD, maintained at the 
WHO country office in Conakry. Patient names and sample 
identifiers recorded in both databases were used as primary 
identifiers for merging; additional variables were used to ver-
ify the match. Inconsistencies between the 2 databases and 
between sample entries for the same patient were resolved, and 
the data were cleaned using Stata 14 (StataCorp). Patients were 
classified into 4 main categories: (1) patients with suspected 
EVD who attended an ETC and had negative results of EBOV 
RT-PCR analysis, (2) patients with EBOV RT-PCR–confirmed 
EVD admitted to the ETC, (3) patients who had negative results 
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of EBOV RT-PCR analysis and died in the community, and (4) 
patients with EBOV RT-PCR–confirmed EVD who died in the 
community (Table 1). Individuals who could not be assigned to 
any category because of missing or conflicting data (n = 151) 
were excluded from further analysis.
To analyze the association between independent variables 
and outcome by using statistical methods, the cleaned EMLab/
WHO database was manually merged with the favipiravir treat-
ment database. The merged database comprised 286 patients 
with EVD, of whom 99 (35%) had been treated with favip-
iravir. Patients were selected for the retrospective study ac-
cording to 6 inclusion/exclusion criteria, specified as follows 
(Supplementary Figure 1). First, children <1 year of age, who 
had not been eligible for compassionate use of favipiravir, were 
also excluded from the nontreatment group, to maintain com-
parability between favipiravir-treated and untreated patients (7 
patients were excluded). Second, patients who received ZMapp 
in combination with favipiravir (12 patients) or were treated 
with IFN-β1a (9 patients) were excluded. Third, the EVD di-
agnosis including the Ct had to be confirmed by EMLab in 
the first specimen collected from the patient (40 patients were 
excluded because of missing EMLab test results for the first 
specimen). Fourth, the first specimen tested had to be a blood 
specimen (11 patients were excluded because testing was done 
on a swab specimen). Fifth, owing to the above criteria, favip-
iravir-treated patients from 2 centers only, ETC Coyah and ETC 
Forécariah, remained in the data set. To maintain comparability 
between favipiravir-treated and untreated patients, the analysis 
was confined to the ETCs in Coyah and Forécariah (20 un-
treated patients were excluded because of admission to various 
other centers). Sixth, EVD cases were admitted to the ETC on 
the same day the diagnostic sample was collected (median, day 
0; interquartile range [IQR], days 0–0), and treatment with favi-
piravir was commenced the day after (median, day 1; IQR, days 
0–1). The treatment group included only patients who survived 
the period between diagnosis and commencement of favipira-
vir treatment. To ensure that the observation of outcome began 
with comparable delay in both the treatment and nontreatment 
groups, all patients who did not survive day 1 (corresponding 
to the median delay between diagnosis and initiation of favip-
iravir treatment) were excluded from the nontreatment group 
(24 patients). This criterion was adopted to prevent allocation of 
patients to the nontreatment group among those who died too 
early for inclusion in the treatment group .
Based on these criteria, 163 patients were eligible for analy-
sis (a line list of patient data is specified in the Supplementary 
Materials). The selection process hardly changed the mortality 
figures: the case-fatality rate (CFR) among favipiravir-treated 
patients included in and excluded from the study was 42.5% (31 
of 73) and 42.3% (11 of 26), respectively; the CFR among non-
treated patients included in and excluded from the study was 
57.8% (52 of 90) and 56.7% (55 of 97), respectively.
We verified with the records that all eligible patients had the 
first specimen collected before treatment was commenced. In 
addition, all Cts were verified using data recorded by the real-
time PCR machines.
Statistical Analysis
Statistical analyses were performed using Stata 14. Categorical 
variables are reported as numbers and percentages of patients. 
Percentages are based on all observations, excluding missing 
values. Continuous variables are reported as medians and IQRs 
for nonnormally distributed variables. Groups were compared 
using the χ2 test for categorical variables or the Mann-Whitney 
U test for continuous variables, with Benjamini-Hochberg cor-
rection for multiple testing. Kaplan-Meier curves and log-rank 
tests were used to assess differences in survival time between 
groups. Univariate associations between independent variables 
and a dichotomous outcome (survival or death) were analyzed 
using logistic regression and displayed with crude (unadjusted) 
odds ratios. To account for confounding factors, multivariate 
logistic regression was used to analyze the association between 
multiple independent variables and the dichotomous outcome.
Ethics
The use of patient data was approved by the National Committee 
of Ethics in Medical Research of Guinea, as well as by the Ethics 
Committee of the Medical Association of Hamburg (permits 
Table 1.  Characteristics of 4636 Patients Tested at the European Mobile Laboratory Unit in Coyah, Guinea
Characteristic
Hospitalized Patients With Suspected EVD Patients Who Died in the Community
Overall EBOV RT-PCR Positive EBOV RT-PCR Negative Overall EBOV RT-PCR Positive EBOV RT-PCR Negative
Patients 813/813 (100) 286/813 (35) 527/813 (65) 3823/3823 (100) 84/3823 (2) 3739/3823 (98)
Female sex 372/813 (46) 151/286 (53) 221/527 (42) 1815/3810 (48) 58/84 (69) 1757/3726 (47)
Age, y 30 (18–45)a 30 (20–43)b 29 (13–45)c 25 (2–55)d 35.5 (23.5–51)e 25 (2–56)f
Malaria RDT positive 194/637 (30) 33/213 (15) 161/424 (38) Not tested Not tested Not tested
Fatal outcome 204/813 (25) 149/286 (52) 55/527 (10) 3823/3823 (100) 84/84 (100) 3739/3739 (100)
Data are no. of patients with the characteristic/no. evaluated (%) or median value (interquartile range), unless otherwise indicated.
Abbreviations: EBOV, Ebola virus; RT-PCR, reverse transcription–polymerase chain reaction; RDT, rapid diagnostic test.
Number of individuals: a, 811; b, 286; c, 525; d, 3785; e, 84; f, 3701
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11/CNERS/14 and PV4910). Compassionate use of favipiravir 
was approved by the National Committee of Ethics in Medical 
Research of Guinea (permit 30/CNERS/15). Written informed 
consent was obtained from all patients who received favipiravir.
RESULTS
Characteristics of the EVD Epidemic Around Coyah
The EMLab unit in Coyah confirmed EVD in 286 of 813 indi-
viduals with suspected EVD (35%) who attended an ETC and 
in 84 of 3823 (2%) who died in the community (Table 1). The 
epidemic curve showed a major wave in February–April and 
a minor wave in May–July (Figure 1). The disease mainly af-
fected adults aged 15–54 years (Supplementary Figure 2). The 
overall CFR in the ETC was 52%, with a downward trend over 
time (Figure 1). The CFR was highest in children aged <5 years 
and adults aged >50 years (Supplementary Figure 3). A malaria 
RDT was performed for 637 individuals (78%) with suspected 
EVD, of whom 194 (30%) tested positive for malaria. Patients 
with a positive  malaria RDT result were younger than those 
with a negative malaria RDT result (median age, 18.5  years 
[IQR, 6–30 years] vs 35 years [IQR, 21–46 years]). Coinfection 
of EBOV with malaria parasites was diagnosed in 33 patients 
(15%) and was most frequent among children <15  years of 
age (Supplementary Figure 3). No major change in the virus 
load as measured via the Ct was observed during the course 
of the epidemic (Supplementary Figure 4). The Cts followed a 
bell-shaped distribution within the measurement range of the 
real-time RT-PCR assay (Supplementary Figure 5). Favipiravir 
monotherapy was administered to 87 of 286 patients with EVD 
(30%); 12 of 286 (4%) received a combination of favipiravir and 
ZMapp, and 9 of 286 (3%) received IFN-β1a [17, 19].
Analysis of Risk Factors Associated With Outcome
We selected 163 (57%) of 286 patients with laboratory-con-
firmed EVD for a retrospective observational study to assess 
associations between potential risk factors, the effect of favi-
piravir treatment, and outcome. The criteria for selecting the 
study subjects aimed to eliminate or reduce various biases in 
the raw data collected under nonstandardized conditions in the 
field (Supplementary Figure 1). The CFR among study patients 
was 51% (83 of 163) and thus representative of the whole data 
set (52%). In addition to Ct and age, which were available for 
all patients, clinical chemistry parameters had been measured 
on admission in a fraction (40%–44%) of the 163 patients 
(Supplementary Figure 10). Fatal outcome was associated with 
a lower Ct (P < .001), a higher BUN level (P = .002), a higher 
creatinine level (P < .001), a higher ALT level (P < .001), a higher 
AST level (P  <  .001), a lower calcium level (P  =  .013), and a 
higher CRP level (P = .006; Supplementary Figure 10). Age and 
Ct showed a clear positive and negative correlation, respectively, 
with the risk of fatal outcome (Supplementary Figures 6 and 7) 
and were further analyzed by regression modeling (discussed 
below). Malaria was not considered in the evaluation because 
the number of coinfected patients was too small for a meaning-
ful analysis.
Analysis of Association Between Favipiravir Treatment and Outcome
The 163 patients with EVD who were eligible for the retro-
spective study (Supplementary Figure 1) included 73 favip-
iravir-treated patients (45%) and 90 (55%) who had not been 
treated with the drug. The characteristics of the 2 groups are 
summarized and compared in Table 2. The CFR among favip-
iravir-treated patients was lower than among untreated patients 
(42.5% [31 of 73] vs 57.8% [52 of 90]). We used logistic regres-
sion models to assess a potential association between favipiravir 
treatment and EVD outcome. Besides drug treatment, the Ct on 
admission and age were included as continuous covariates in 
the regression model, owing to their strong correlation with the 
risk of fatal outcome (Supplementary Figures 6 and 7). Clinical 
chemistry parameters could not be considered because of large 
numbers of missing values. In both unadjusted and multivariate 
analyses, a higher Ct on admission (P < .001 in both analyses) 
and a younger age (P =  .002 and P <  .001, respectively) were 
80
60
40
20
0
80
60
40
20
0
Hospital cases(n) CFR (%)
Fe
b 
20
15
M
ar
 2
01
5
A
pr
 2
01
5
M
ay
 2
01
5
Ju
n 
20
15
Ju
l 2
01
5
A
ug
 2
01
5
Se
p 
20
15
O
ct
 2
01
5
N
ov
 2
01
5
Community deaths
200
(n)
160
120
80
40
0
Fe
b 
20
15
M
ar
 2
01
5
A
pr
 2
01
5
M
ay
 2
01
5
Ju
n 
20
15
Ju
l 2
01
5
A
ug
 2
01
5
Se
p 
20
15
O
ct
 2
01
5
N
ov
 2
01
5
EBOV RT-PCR positive
EBOV RT-PCR negative
Case fatality rate
Figure 1. Epidemic curve of Ebola virus disease (EVD) cases diagnosed at the 
European Mobile Laboratory unit during the study period. A, Ebola virus (EBOV)–
specific reverse transcription–polymerase chain reaction (RT-PCR) results for 813 
patients with suspected EVD who attended an Ebola treatment center, and case-fa-
tality rates (CFRs) among hospitalized patients with EVD over time. B, EBOV RT-PCR 
results for 3823 individuals who died in the community.
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statistically significant predictors of survival (Table 3). The pos-
itive effect of favipiravir treatment had borderline significance 
in the unadjusted model (P =  .053) and lost statistical signifi-
cance in the multivariate model (P = .11; Table 3). The corre-
sponding regression curves for the association between Ct and 
the probability of a fatal outcome indicated an up to 18% lower 
risk of death among favipiravir-treated patients as compared to 
untreated patients (Figure 2). This effect reached its maximum 
in the Ct range of 20–24, depending on age (Supplementary 
Figure 8).
Kaplan-Meier analysis of survival time was performed under 
2 assumptions. First, we assumed that survivors were lost to fol-
low-up on discharge, and therefore we censored them at that 
day. This analysis revealed a statistically significant longer sur-
vival time in the favipiravir-treated group (P  =  .003; Figure 
3). However, favipiravir-treated survivors stayed significantly 
longer in the ETC than untreated survivors, owing to the 10-day 
treatment course (median time between sampling and dis-
charge, 14 days [IQR, 10–17 days] vs 9 days [IQR, 6–12 days]; 
P < .001), which introduces a bias in the number of patients at 
risk. Because the available data did not suggest that a survivor 
died from EVD after discharge (although this possibility cannot 
be firmly excluded), we performed a second analysis that 
assumed a 30-day observation period for all patients. This anal-
ysis also indicated a longer survival time, although with a lower 
statistical significance (P = .015; Supplementary Figure 9).
Table 2. Characteristics on Admission of 163 Patients With Ebola Virus Disease, by Favipiravir Treatment Status
Characteristic Reference Range
Treated Patients (n = 73) Nontreated Patients (n = 90)
PaValue No. Value No.
Ebola treatment center, patients, no. 73 90 <.001
 Forécariah, Guinea NA 18  2   
 Coyah, Guinea NA 55  88   
Age, y NA 30 (23–40) 73 29 (18–40) 90 .170
Female sex NA 41 (56.2) 73 55 (61.1) 90 .523
Malaria RDT positive NA 10 (14.5) 69 10 (12.7) 79 .745
Ct NA 22.3 (18.8–26.5) 73 20.2 (17.8–24.1) 90 .171
 Blood chemistry parameter       
 Glucose level, mmol/L 4.1–6.6 4.8 (3.6–6.5) 44 4.1 (3–5) 27 .209
 BUN level, mmol/L 2.5–7.9 6.3 (3.8–11.8) 44 12.4 (4.1–27.3) 27 .201
 Creatinine level, µmol/L 53–106 104 (79–153) 44 216 (89–713) 27 .201
 Total bilirubin level, µmol/L 3.4–27.4 9 (8–12) 43 13 (8–18) 26 .201
 Albumin level, g/L 33–55 32 (28–36) 44 30 (26–35) 27 .209
 ALT level, U/L 10–47 115 (67–356) 44 277 (108–444) 27 .209
 AST level, U/L 11–38 502 (154–1290) 42 1058 (323–2000) 25 .201
 CK level, U/L 30–380 917 (323–2032) 44 1443 (718–2534) 25 .209
 Amylase level, U/L 14–97 98 (64–161.5) 44 120 (62–164) 27 .639
 Sodium level, mmol/L 128–145 130 (126–135) 44 130 (128–131) 26 .765
 Potassium level, mmol/L 3.6–5.1 4 (3.5–4.5) 41 4.5 (3.7–5.1) 24 .209
 Calcium level, mmol/L 2.00–2.58 2.15 (2.03–2.21) 44 2.05 (1.85–2.19) 27 .209
 CRP level, mg/L <7.5 20.3 (8.3–58.7) 44 24.5 (13.9–68.4) 24 .525
Data are median value (interquartile range) or no. (%) of patients, unless otherwise indicated.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CK, creatine kinase; CRP, C-reactive protein; ETC, Ebola treatment center; NA, not 
applicable; RDT, rapid diagnostic test.
aBy the χ2 test (for categorical variables) and the Mann-Whitney U test (for continuous variables), with the Benjamini-Hochberg correction for multiple testing.
Table 3. Logistic Regression of the Association of Independent Variables With a Fatal Outcome of Ebola Virus Disease
Variable Deaths/Total Cases, No. (%)
Unadjusted Model Multivariate Model
OR (95% CI) P OR (95% CI) P
 EBOV RT-PCR Ct (continuous; n = 163) 83/163 (50.9) .68 (.61–.77) <.001 .64 (.56–.74) <.001
Age, y (continuous; n = 163) 83/163 (50.9) 1.03 (1.01–1.05) .002 1.06 (1.03–1.09) <.001
Favipiravir treatment (n = 163)      
 No 52/90 (57.8) 1 (reference)  1 (reference)  
 Yes 31/73 (42.5) .54 (.29–1.01) .053 .48 (.20–1.18) .11
Abbreviations: CI, confidence interval; Ct, cycle threshold; EBOV, Ebola virus; OR, odds ratio; RT-PCR, reverse transcription–polymerase chain reaction.
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Kinetics of Laboratory Parameters During the Course of EVD
Ct and clinical chemistry parameters were measured during 
hospitalization in a fraction of the 163 study patients. 
Survivors showed a decline in virus load, and negative results 
of RT-PCR analysis of blood specimens usually began to ap-
pear between day 3 and day 18 (Supplementary Figure 11). 
Patients who died maintained a high virus load until death, 
although some patients who died at later stage (ie, after day 
10)  showed a moderate decline in virus load. There were 
no apparent differences in the virus load kinetics between 
favipiravir-treated and untreated patients. Follow-up blood 
chemistry findings were only available for favipiravir-treated 
patients (Supplementary Figure 11). Characteristic pathologic 
patterns in fatal cases included (1) substantial alterations in 
glucose levels, with hyperglycemia and hypoglycemia; (2) 
hyperkalemia; (3) increasing creatinine, BUN, bilirubin, CK, 
and CRP values; (4) decreasing calcium and albumin values; 
and (5) increasing ALT and AST values, followed by a decreas-
ing trend. Similar although mostly less prominent alterations 
were observed in survivors. However, survival was basically 
associated with normalization of values around 10 days after 
commencement of favipiravir treatment.
DISCUSSION
We present an analysis of laboratory, demographic, treatment, 
and outcome data collected during the 10-month EMLab oper-
ation in Coyah. Compared with the first site of EMLab opera-
tion in Guéckédou, in the region of Forest Guinea, the much 
higher number of samples tested from patients who died in the 
community is apparent, with 3823 tests in Coyah versus 563 in 
Guéckédou [15]. This resulted from intensified active surveil-
lance and contact-tracing efforts that were implemented during 
the later phase of the epidemic. However, although just 2% of 
patients (84 of 3823)  who died in the community had EVD 
diagnosed, this number still accounted for 36% (84 of 233) of 
all fatal EVD cases diagnosed by the laboratory in Coyah (149 
in the ETC plus 84 in community; Table 1). Thus, more than a 
year after the outbreak started in Guinea, these estimates sug-
gest that one third of all patients with EVD in this region did 
not attend the ETC and died in the community, despite major 
efforts to increase awareness in communities. On one hand, 
these patients could not benefit from supportive care or even 
specific treatment, and on the other hand, they maintained 
the transmission chains in the community. These observations 
underline the importance of community engagement and trust 
building in outbreak situations.
The findings on risk factors for a fatal outcome—age, virus 
load (Ct), and blood chemistry findings on admission—largely 
confirm results of previous studies [2–15]. However, the kinetics 
of blood chemistry parameters provide further insight into the 
pathophysiology of EVD and may guide supportive manage-
ment of patients. A key manifestation is a progressive impair-
ment of renal function, as evidenced by increasing creatinine, 
BUN, and potassium values until death. Markers of cell damage, 
such as ALT, AST, and CK, may tend to normalize before death 
and are therefore not reliable prognostic marker during patient 
management. Alterations in glucose and electrolyte levels are 
amenable to supportive treatment.
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Figure 3. Kaplan-Meier analysis of survival time among patients in the retro-
spective study. The analysis was performed under the assumption that survivors 
were lost to follow-up on discharge. Therefore, survivors were censored at dis-
charge (small vertical ticks on the curves). Numbers of patients at risk are indi-
cated for the nontreatment (A) and treatment (B) groups. For Kaplan-Meier analysis 
without censoring at the time of discharge, see Supplementary Figure 9.
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Figure 2. Multivariate logistic regression model for the association between 
the cycle threshold (Ct), age, favipiravir treatment status, and probability of a fatal 
outcome. The association between the Ct and the probability of death, depending 
on favipiravir treatment status, is displayed by regression curves. The curves were 
calculated for a mean age of 31.5 years among patients in the analysis. The esti-
mated improvement in the chance of survival due to favipiravir treatment (absolute 
reduction in the probability of dying is defined as the difference between the “No 
treatment” curve and the “Favipiravir” curve) is shown. The curves were calculated 
from the parameters of the multivariate logistic regression analysis of data from 
the 163 patients with Ebola virus disease (EVD) included in the retrospective study 
(Table 3). For the age dependency of the curves, see Supplementary Figure 8.
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Before favipiravir was offered to patients on a compas-
sionate-use basis, it had been evaluated in a clinical trial, the 
so-called JIKI trial in Guinea [18]. The trial was performed at 
4 ETCs supported by different laboratories and relied on his-
torical controls. It revealed a trend of efficacy in patients with a 
low virus load as defined by a Ct ≥ 20. However, a statistically 
significant effect in this subgroup could not be demonstrated. 
The retrospective study presented here on compassionate use 
of the drug features some favorable methodological conditions 
for analysis of outcome predictors. First, only 2 ETCs were 
included; second, a single laboratory generated all Cts; and 
third, patients who were treated with favipiravir and those who 
were not treated were managed at the same time. On the other 
hand, favipiravir was not evaluated in the controlled setting of a 
clinical trial. While we have made great efforts to reduce biases 
in the raw field data by using a set of criteria, the retrospec-
tive study design still has serious limitations, and data arising 
from the study have to be interpreted with care. A key limita-
tion is the lack of randomization. Patients who were treated are 
clearly identifiable, while retrospectively defining an unbiased 
nontreatment (ie, control) group is difficult. The field data-
base is likely to include nontreated patients who were too sick 
to provide consent, who were not able to take oral drugs, or 
who died before they could provide consent or before treatment 
could be commenced; these aspects are not recorded. We tried 
to mitigate this bias by excluding all patients who died during 
day 0 and day 1 from the nontreatment group. However, this 
approach is arbitrary and does not guarantee an unbiased con-
trol group. The Kaplan-Meier curves still show higher mortality 
in the nontreatment group on day 2 and day 3, which might 
be by chance, due to a residual bias, or due to a higher virus 
load on admission (Ct  ≤  20, 59% in the nontreatment group 
vs 42% in the treatment group; Supplementary Figure 6). The 
latter is taken into account in the multivariate analysis. Despite 
these limitations, the obtained data complement the results 
of the JIKI trial. The regression model reveals a trend toward 
improved survival, with an estimated 18% reduction in the CFR 
depending on Ct and age. However, the effect did not reach sta-
tistical significance, similar to the JIKI trial data. The positive 
trend is supported by the Kaplan-Meier analysis, which sug-
gested a prolongation of the survival time.
Pharmacokinetics data for patients with EVD enrolled in the 
JIKI trial revealed that drug concentrations were lower than 
targeted levels [21]. Therefore, it is conceivable that administer-
ing higher doses of favipiravir, increasing its bioavailability, or 
modulating its metabolism could enhance its therapeutic effect. 
However, case reports on patients with Lassa fever or norovirus 
infection who received favipiravir at similar doses as in the JIKI 
trial and the present study describe putative adverse events along 
with symptomatic responses [22, 23]. In conclusion, the obser-
vations made so far with favipiravir, including those presented 
here, call for further preclinical and clinical studies to better 
understand pharmacokinetics, pharmacodynamics, and adverse 
events at various dosing schemes and pharmaceutical forms.
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